University Of Kentucky Researcher Awarded MERIT Extension For Study Of Third World Killer

LEXINGTON, KY (Sept. 21, 1998) - Salvatore Turco, Ph.D., professor of biochemistry, University of Kentucky College of Medicine, has received a five-year extension on a National Institutes of Health (NIH) Method to Extend Research in Time (MERIT) award. The National Institute of Allergy and Infectious Diseases at the NIH has awarded Turco $1,583,700 to continue his study, "Glycoconjugates of Leishmania."

Leishmania donovani, a one-cell parasite, is one of the world's major pathogens. It afflicts 10 to 20 million people in Mediterranean and Third World countries. The parasite is transmitted by sand flies and results in the disease called leishmaniasis. Leishmaniasis, which often results in death, is a problem for residents, travelers, and U.S. soldiers stationed in the Middle East. It was a particular issue during Desert Storm, Turco said. Symptoms include sores, high fever and severe disfigurement. There are only antiquated drugs used for cures and preventive measures, despite scientists' understanding of the biology of the parasite's attack on the human body.

"We are trying to determine how the parasite survives in the human host," Turco said. "We suspect there is something unusual about the Leishmania cell surface that we feel is responsible for the parasite to invade the body and survive with impunity."

Leishmania's cell surface contains a complex molecule made up of sugar, fat and phosphate, called a lipophosphoglycan, that is used for defensive purposes. The molecule prevents the host animal's white cells, called macrophages, from being activated and attacking the parasite. Without the lipophosphoglycan, the parasite is destroyed by macrophages.

Researchers hope that the molecule might play a key role in creating treatments or preventive therapies for leishmaniasis.


Contact: Kim Cumbie
(606) 323-6363
University of Kentucky Medical Center

Page: 1

Related biology news :

1. Indiana University, EPA to study airborne PCBs
2. University of Alberta researcher looks for clues to mysterious disease
3. Northeastern University receives $12.4 million NSF grant for creation of nanomanufacturing institute
4. Washington University in St. Louis leads group studying aging process
5. Tufts University establishes $4 million dollar tissue engineering resource center
6. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
7. As informatics grows, Indiana University helps set research agenda
8. University of Arizona licenses patent for natural fungicide
9. Washington University in St. Louis plays key role in sequencing moss genome
10. University of Pittsburgh receives $10 million grant for head and neck cancer
11. Clemson University spin-off uses corn to make plastics, provide cleaner air

Post Your Comments:

(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded ... of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for ... fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
Breaking Biology Technology:
Cached News: